MCID: HPT023
MIFTS: 90

Hepatocellular Carcinoma malady

Categories: Genetic diseases, Rare diseases, Liver diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Hepatocellular Carcinoma

About this section
Sources:
50OMIM, 33LifeMap Discovery®, 11Disease Ontology, 46NIH Rare Diseases, 13DISEASES, 52Orphanet, 68UniProtKB/Swiss-Prot, 25GTR, 12diseasecard, 48Novoseek, 36MedlinePlus, 37MeSH, 66UMLS, 28ICD10, 30ICD9CM, 43NCIt, 29ICD10 via Orphanet, 38MESH via Orphanet, 67UMLS via Orphanet, 35MedGen, 60SNOMED-CT, 62The Human Phenotype Ontology
See all MalaCards sources

Aliases & Descriptions for Hepatocellular Carcinoma:

Name: Hepatocellular Carcinoma 50 33 11 13 52 68 12 48
Liver Cancer 11 46 13 68 36
Hcc 11 46 52 68
Hepatocellular Cancer 46 68 25
Liver Neoplasm 11 13 25
Hepatoma 11 46 68
Adult Primary Hepatocellular Carcinoma 11 66
Primary Malignant Neoplasm of Liver 11 66
Malignant Neoplasm of Liver 11 66
Hepatoblastoma, Somatic 50 12
Liver Neoplasms 37 66
Hepatic Cancer 11 48
Hepatoblastoma 52 66
Malignant Neoplasm of Liver, Not Specified As Primary or Secondary 11
Epithelial Hepatic and Intrahepatic Bile Duct Neoplasm 11
Non-Resectable Primary Hepatic Malignant Neoplasm 11
Hepatocellular Carcinoma, Childhood Type, Somatic 50
Liver and Intrahepatic Biliary Tract Carcinoma 66
Resectable Malignant Neoplasm of the Liver 11
Primary Malignant Neoplasm of Liver Nos 11
Malignant Neoplasm of Liver Unspecified 11
Resectable Malignant Neoplasm of Liver 11
 
Malignant Neoplasm of Liver, Primary 11
Malignant Hepato-Biliary Neoplasm 11
Hepatocellular Carcinoma, Somatic 50
Malignant Hepatobiliary Neoplasm 66
Hepatocellular Carcinoma, Adult 46
Hepatocellular Cancer, Somatic 50
Adult Hepatocellular Carcinoma 52
Primary Tumor of the Liver 46
Liver Cell Carcinoma Adult 46
Carcinoma, Hepatocellular 37
Malignant Tumor of Liver 11
Liver Cell Carcinoma 68
Primary Liver Cancer 11
Liver Cancer Adult 46
Ca Liver - Primary 11
Neoplasm of Liver 11
Hepatic Neoplasm 11
Liver Carcinoma 66
Hepatocarcinoma 46
Adult Hepatoma 11
Adult Hcc 52
Lcc 68

Characteristics:

Orphanet epidemiological data:

52
hepatoblastoma:
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe),1-9/1000000 (Europe); Age of onset: Childhood,Infancy,Neonatal; Age of death: early childhood,infantile
adult hepatocellular carcinoma:
Inheritance: Not applicable
hepatocellular carcinoma:
Inheritance: Not applicable; Prevalence: 1-9/100000 (United States),1-5/10000 (Europe); Age of onset: All ages; Age of death: adult

HPO:

62
hepatocellular carcinoma:
Inheritance: autosomal dominant inheritance, somatic mutation


Classifications:

Orphanet: 52 
Rare hepatic diseases


External Ids:

OMIM50 114550
Disease Ontology11 DOID:3571, DOID:684, DOID:916
ICD1028 C22.0, C22.9
ICD9CM30 155.0, 155.2
ICD10 via Orphanet29 C22.2, C22.0
MESH via Orphanet38 D018197, D006528
UMLS via Orphanet67 C0206624

Summaries for Hepatocellular Carcinoma

About this section
MedlinePlus:36 Your liver is the largest organ inside your body. it helps your body digest food, store energy, and remove poisons. primary liver cancer starts in the liver. metastatic liver cancer starts somewhere else and spreads to your liver. risk factors for primary liver cancer include having hepatitis b or c heavy alcohol use having cirrhosis, or scarring of the liver having hemochromatosis, an iron storage disease obesity and diabetes symptoms can include a lump or pain on the right side of your abdomen and yellowing of the skin. however, you may not have symptoms until the cancer is advanced. this makes it harder to treat. doctors use tests that examine the liver and the blood to diagnose liver cancer. treatment options include surgery, radiation, chemotherapy, or liver transplantation. nih: national cancer institute

MalaCards based summary: Hepatocellular Carcinoma, also known as liver cancer, is related to glomerulonephritis and plasmacytoma, and has symptoms including hepatomegaly, hepatosplenomegaly and abdominal pain. An important gene associated with Hepatocellular Carcinoma is AXIN1 (Axin 1), and among its related pathways are Pathways in cancer and Wnt Signaling Pathways: beta-Catenin-independent Wnt/PCP Signaling Pathways. The drugs interferon alfa-2a and interferon alfa-2b have been mentioned in the context of this disorder. Affiliated tissues include the liver, liver and breast, and related mouse phenotypes are cellular and liver/biliary system.

Disease Ontology:11 A gastrointestinal system cancer that is located in the liver.

UniProtKB/Swiss-Prot:68 Hepatocellular carcinoma: A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes.

OMIM:50 Hepatocellular carcinoma is the major histologic type of malignant primary liver neoplasm. It is the fifth most common... (114550) more...

Wikipedia:69 Hepatocellular carcinoma (HCC), also called malignant hepatoma, is the most common type of liver cancer. more...

Related Diseases for Hepatocellular Carcinoma

About this section

Diseases related to Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 366)
idRelated DiseaseScoreTop Affiliating Genes
1glomerulonephritis31.6APC, CTNNB1, MET, PIK3CA, TP53
2plasmacytoma31.3AFP, CTNNB1, TP53
3colorectal cancer31.2APC, AXIN1, CASP8, CTNNB1, GLUL, MET
4childhood hepatocellular carcinoma12.4
5aflatoxins-related hepatocellular carcinoma12.0
6fibrolamellar carcinoma11.6
7gallbladder papillomatosis11.5AFP, CTNNB1, GPC3, MET, PIK3CA, TP53
8emerinopathy11.4AXIN1, CTNNB1, GPC3, TP53
9hepatitis11.4
10spinal cord primitive neuroectodermal neoplasm11.4AFP, CTNNB1, GPC3, TP53
11nasal cavity adenocarcinoma11.4AFP, CTNNB1, GPC3, TP53
12brachyolmia11.4AFP, CASP8, CTNNB1, PIK3CA, TP53
13arrhythmogenic right ventricular cardiomyopathy11.4APC, AXIN1, CTNNB1, TP53
14medulloblastoma11.4APC, AXIN1, CASP8, CTNNB1, TP53
15ruijs-aalfs syndrome11.4
16ovarian small cell carcinoma11.4CTNNB1, PIK3CA, TP53
17mature b-cell neoplasm11.4AXIN1, CTNNB1, TP53
18extra-adrenal pheochromocytoma11.3GPC3, PIK3CA, TP53
19myelophthisic anemia11.3APC, CTNNB1, PIK3CA
20mucinous adenocarcinoma11.3AFP, APC, TP53
21hemangioma of lung11.3AFP, GPC3, TP53
22hepatocellular fibrolamellar carcinoma11.3
23desmoid disease, hereditary11.3APC, AXIN1, CTNNB1, GLUL
24hepatocellular carcinoma11.3AFP, APC, AXIN1, CASP8, CDKN3, CTNNB1
25lobular neoplasia11.3CTNNB1, MET, TP53
26progeria11.3GPC3, PIK3CA, TP53
27lethal congenital contracture syndrome11.3
28ehlers-danlos syndrome, type viic11.3APC, CTNNB1, GLUL
29ectodermal dysplasia with natal teeth, turnpenny type11.3AFP, GPC3, MET
30pseudoangiomatous stromal hyperplasia11.3PIK3CA, TP53
31herpes simplex encephalitic 611.3APC, CTNNB1, TP53
32trachea sarcoma11.2CTNNB1, PIK3CA, TP53
33brown-vialetto-van laere syndrome11.2AFP, CTNNB1, TP53
34blepharochalasis11.2CASP8, PIK3CA, TP53
35urticaria11.2CASP8, MET, TP53
36atypical lipomatous tumor11.1AFP, GPC3
37tamoxifen-related endometrial lesion11.1PIK3CA, TP53
38epithelial predominant pulmonary blastoma11.1AFP, CTNNB1
39hepatitis c virus11.1
40ovary serous adenocarcinoma11.0AFP, GPC3
41hepatocellular clear cell carcinoma11.0
42sclerosing hepatic carcinoma11.0
43malignant hyperthermia susceptibility11.0APC, TP53
44hepatitis b10.9
45leukoencephalopathy, cerebral calcifications, and cysts10.9
46sm-ahnmd10.9MET, TP53
47ampulla of vater squamous cell carcinoma10.9APC, TP53
48hepatitis c10.8
49colver steer godman syndrome10.8APC, TP53
50ovarian cancer, somatic10.8CTNNB1, MUT, PIK3CA

Comorbidity relations with Hepatocellular Carcinoma via Phenotypic Disease Network (PDN):


Active Peptic Ulcer DiseaseAcute Cystitis
Alcoholic Liver CirrhosisDeficiency Anemia
Hepatic EncephalopathyIntrahepatic Gall Duct Cancer
Portal HypertensionProtein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatocellular Carcinoma:



Diseases related to hepatocellular carcinoma

Symptoms for Hepatocellular Carcinoma

About this section

Symptoms by clinical synopsis from OMIM:

114550

Clinical features from OMIM:

114550

HPO human phenotypes related to Hepatocellular Carcinoma:

id Description Frequency HPO Source Accession
1 hepatocellular carcinoma HP:0001402
2 micronodular cirrhosis HP:0001413
3 subacute progressive viral hepatitis HP:0006572

UMLS symptoms related to Hepatocellular Carcinoma:


hepatomegaly, hepatosplenomegaly, abdominal pain, malaise, constipation, diarrhea, dyspepsia, heartburn, nausea and vomiting, gastrointestinal gas

Drugs & Therapeutics for Hepatocellular Carcinoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Feridex I.V.16 FERUMOXIDES Advanced Magnetics February 1996
FDA Label: -
Disease/s that Drug Treats:liver cancer
Indications and Usage:16 -
DrugBank Targets: -
Mechanism of Action:16 
Target: -
Action: -
FDA: -
2
Nexavar16 42 SORAFENIB TOSYLATE Bayer/Onyx December 2005
FDA Label: Nexavar
Disease/s that Drug Treats:Renal Cell Carcinoma
Indications and Usage:16 NEXAVAR is a kinase inhibitor indicated for the treatment of Unresecta ble hepatocellular carcinoma (1.1) adjust thyroid repla cement therapy in patients with thyroid ca ncer. (5.12) Advanced renal cell carcinoma (1.2) Locally recurrent or meta static, progressive, differentiated thyroid carcinoma refractory to ra dioactive iodine treatment (1.3)
DrugBank Targets:14 1. Serine/threonine-protein kinase B-raf;2. RAF proto-oncogene serine/threonine-protein kinase;3. Vascular endothelial growth factor receptor 3;4. Vascular endothelial growth factor receptor 2;5. Receptor-type tyrosine-protein kinase FLT3;6. Platelet-derived growth factor receptor beta;7. Mast/stem cell growth factor receptor Kit;8. Fibroblast growth factor receptor 1;9. Proto-oncogene tyrosine-protein kinase receptor Ret;10. Vascular endothelial growth factor receptor 1
Mechanism of Action:16 
Target: c-CRAF, BRAF and mutant BRAF, KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß
Action: inhibitor
FDA: Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro.Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surfacekinases (KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß). Several of thesekinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumorgrowth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumorangiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosiswer e obser ved in models of HCC, RCC, and DTC.

Drugs for Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 503)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DoxilApproved June 1999Phase 4, Phase 3, Phase 2, Phase 1167631703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
2
SimvastatinPhase 450379902-63-954454
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
79902-63-9
AC-1530
AC1L1H1F
AKOS005111006
ARONIS24119
BCBcMAP01_000007
BIDD:GT0769
BPBio1_001001
BRD-K22134346-001-05-8
BRN 4768037
BSPBio_000909
BSPBio_002337
Bio-0672
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
C25H38O5
CCRIS 7558
CHEBI:9150
CHEMBL1064
CID54454
CPD000718785
Cholestat
Coledis
Colemin
Corolin
D00434
D019821
DRG-0320
Denan
DivK1c_006991
Eucor
HMS1570N11
HMS1922H13
HMS2089D12
HMS2093E06
HSDB 7208
InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
KBio1_001935
KBio2_002197
KBio2_004765
KBio2_007333
KBio3_001557
KBioGR_001244
KBioSS_002197
KS-1113
Kolestevan
L 644128-000U
LS-46264
Labistatin
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
MK 0733
MK 733
MK-0733
MK-733
MK733
MLS001304029
MLS001333077
MLS001333078
 
MLS002154038
Medipo
Modutrol
MolPort-002-507-345
MolPort-002-885-862
NCGC00017324-01
NCGC00017324-02
NCGC00017324-03
Nivelipol
Nor-Vastina
Pantok
Pepstatin
Prestwick0_000865
Prestwick1_000865
Prestwick2_000865
Prestwick3_000865
Prestwick_171
Rechol
Rendapid
S1792_Selleck
S6196_SIGMA
SAM002589969
SMR000718785
SPBio_001881
SPBio_002830
SPECTRUM1504236
STK801938
Simcor
Simovil
Simvast CR
Simvastatin
Simvastatin & Primycin
Simvastatin (JAN/USP/INN)
Simvastatin [USAN:INN:BAN]
Simvastatin [Usan:Ban:Inn]
Simvastatin lactone
Simvastatin, Compactin
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
Sivastin
SpecPlus_000895
Spectrum2_001671
Spectrum3_000669
Spectrum4_000632
Spectrum5_001428
Spectrum_001717
Statin
Synvinolin
TNP00259
UNII-AGG2FN16EV
Valemia
Vasotenal
Velostatin
Vytorin
ZINC03780893
Zocor
Zocor (TN)
Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin
Zocord
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta
nchembio790-comp16
simvastatin
3
protease inhibitorsPhase 4, Phase 3, Phase 1, Phase 2, Phase 05157
Synonyms:
 
protease inhibitors
4
MetforminPhase 4, Phase 3, Phase 2, Phase 11701657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
5
PropranololPhase 4, Phase 3, Phase 2210525-66-64946
Synonyms:
(+-)-Propranolol
(1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol
(R)-(+)-propranolol
(S)-(-)-PROPRANOLOL
1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane
1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol
1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol
1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol
1-Isopropylamino-3-(1-naphthyloxy)-2-propanol
1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
13013-17-7
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9CI)
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)- (9CI)
3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol
4199-09-1
4199-10-4
525-66-6
AB00053537
AC1L1JA4
AC1Q1QBV
AC1Q1QC0
AKOS000588816
AY 64043
AY-20694
Anaprilin
Anapriline
Angilol
Apsolol
Avlocardyl
BPBio1_001040
BRD-A10070317-003-06-9
BSPBio_000944
BSPBio_002682
Bedranol
Beprane
Berkolol
Beta Neg
Beta-Neg
Beta-Propranolol
Beta-Tablinen
Beta-Timelets
Betachron
Betadren
Betalong
Bio-0732
Bio1_000367
Bio1_000856
Bio1_001345
C07407
C16H21NO2
CBDivE_006180
CCRIS 3082
CHEBI:8499
CHEMBL27
CID4946
Cardinol
Caridolol
Corpendol
D,L-Propranolol
D08443
DB00571
DL-Propranolol hydrochloride
Deralin
DivK1c_000023
Dl-Propranolol Hydrochloride
Dociton
Duranol
EINECS 208-378-0
EINECS 235-867-6
Efektolol
Elbrol
Etalong
Euprovasin
Frekven
HMS2090L21
Herzbase
ICI 45520
IDI1_000023
INDERIDE-40/25
INDERIDE-80/25
Ikopal
Inderal
Inderal La
Inderal hydrochloride
Inderalici
Inderex
Inderide
Inderol
Indobloc
InnoPranXL
 
Innopran XL
Intermigran
KBio1_000023
KBio2_002515
KBio2_005083
KBio2_007651
KBio3_001766
KBio3_001902
KBio3_002993
KBioGR_001347
KBioGR_001684
KBioGR_002515
KBioSS_002523
Kemi
Kemi S
L000679
LS-122410
LS-184129
Lopac0_000896
Migrastat
MolPort-001-794-623
NCGC00015798-07
NCGC00024690-02
NCGC00024690-03
NINDS_000023
NSC91523
Naprilin
Obsidan
Obzidan
Oposim
Oprea1_304193
PDSP1_000767
PDSP1_001607
PDSP1_001608
PDSP2_000755
PDSP2_001591
PDSP2_001592
Prano-Puren
Pranolol
Prestwick0_000952
Prestwick1_000952
Prestwick2_000952
Prestwick3_000952
Pronovan
Propanalol
Propanix
Propanolol
Propanolol [INN-Spanish]
Prophylux
Propranalol
Propranolol
Propranolol (INN)
Propranolol (TN)
Propranolol Hcl
Propranolol Hcl Intensol
Propranolol Hydrochloride
Propranolol [INN:BAN]
Propranololo
Propranololo [DCIT]
Propranololum
Propranololum [INN-Latin]
Propranur
Proprasylyt
Pylapron
R,S-Propranolol Hydrochloride
Racemic propranolol
Rapynogen
Reducor
Reducor Line
Reducor line
SPBio_001361
SPBio_001658
SPBio_003093
STK735510
Sagittol
Sawatal
Servanolol
Sloprolol
Spectrum2_001301
Spectrum2_001699
Spectrum3_000883
Spectrum3_001071
Spectrum4_000974
Spectrum4_001222
Spectrum5_000751
Sumial
Tesnol
UNII-9Y8NXQ24VQ
b-Propranolol
beta-Propranolol
cMAP_000071
etalong
propranolol
propranololo
β-Propranolol
6vitamin dPhase 4, Phase 2, Phase 3, Phase 1, Phase 01607
7
DrospirenonePhase 410167392-87-468873
Synonyms:
(6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3',4',6,6a,7,8,9,10,11,12,13,14,15,15a,16-Hexadecahydro-10,13-dimethylspiro-(17H-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2'(5'H)-furan)-3,5'(2H)-dione
1, 2-Dihydrospirorenone
1,2-Dihydrospirorenone
1,2-dihydro-spirorenone
15,16]-17alpha-pregn-4-ene-21,17-carbolactone
15-beta,16-beta-Dimethylene-3-oxo-17-alpha-pregn-4-ene-21,17-carbolactone
15beta,16beta-Dimethylene-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
17-Hydroxy-6beta,7beta:15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21-carboxylic acid, gamma-lactone
3-oxo-6alpha,7alpha,15alpha,16alpha-tetrahydro-7'H,16'H-dicyclopropa[6,7
6-beta,7-beta
67392-87-4
6beta,7Beta
6beta,7beta
6beta,7beta,15beta,16beta-dimethylen-3-oxo-17alpha-pregn-4-en-21,17-carbolacton
6beta,7beta,15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21,17 carbolactone
6β,7β,15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17 carbolactone
AC1L2AMM
Angeliq, Drospirenone
BRN 4765500
C035144
C24H30O3
CCRIS 6523
CHEBI:50838
 
CHEMBL1509
CID68873
D03917
DB01395
DRSP
Dehydrospirorenone
Dihydrospirorenone
Drospirenona
Drospirenona [INN-Spanish]
Drospirenona [inn-spanish]
Drospirenone
Drospirenone (JAN/USAN/INN)
Drospirenone [INN]
Drospirenonum
Drospirenonum [INN-Latin]
Drospirenonum [inn-latin]
EINECS 266-679-2
LS-146115
S1377_Selleck
SH-470
Spiro(17H-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2'(5'H)-furan)-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (6R-(6alpha,7alpha,8beta,9alpha,10beta,13beta,14alpha,15alpha,16alpha,17beta
UNII-N295J34A25
ZINC03927200
ZK 30595
ZK-30595
ZK30595
8
PirarubicinPhase 4, Phase 3, Phase 21872496-41-4
Synonyms:
Adriamycin, tetrahydropyranyl
 
THP-Adm
THP-Doxorubicin
Theprubicin
9
CefazolinPhase 410525953-19-9656510, 33255
Synonyms:
(6R, 7R)-3-[[(5-Methyl-1,3,4-thiadiazol-2- yl)thio]methyl]-8-oxo-7-[[1H-tetrazol-1- yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2- ene-2-carboxylic acid
(6R,7R)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1H-tetrazol-1-yl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
(6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R-trans)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(((1H-tetrazol-1-yl)acetyl)-amino)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
25953-19-9
27164-46-1
3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-7beta-[(1H-tetrazol-1-ylacetyl)amino]-3,4-didehydrocepham-4-carboxylic acid
7-(1-(1H-)-Tetrazolylacetamido)-3-(2-(5-methyl-1,3,4-thiadiazolyl)thiomethyl)delta3-cephem-4-carboxylic acid
AC-16010
AC1L1P98
AC1Q6LOT
BPBio1_000762
BRN 4169371
BSPBio_000692
BSPBio_001939
Bio-0576
C06880
C14H14N8O4S3
CEZ
CHEBI:474053
CHEMBL1435
CID33255
Cefamezin
Cefamezine
Cefazolin (USP)
Cefazolin [USAN:INN]
Cefazolina
Cefazolina [INN-Spanish]
Cefazoline
Cefazoline [INN-French]
Cefazolinum
Cefazolinum [INN-Latin]
Cephamezine
Cephazolidin
Cephazolin
 
Cephazolin Sodium
Cephazoline
D02299
DivK1c_000014
EINECS 247-362-8
Elzogram
HSDB 3213
IDI1_000014
KBio1_000014
KBio2_000546
KBio2_003114
KBio2_005682
KBio3_001159
KBioGR_000734
KBioSS_000546
LS-150084
Lopac0_000274
MLS001032060
MLS001049010
MolPort-002-507-461
NCGC00159465-02
NINDS_000014
NSC291561
Prestwick0_000736
Prestwick1_000736
Prestwick2_000736
Prestwick3_000736
SMR000387025
SPBio_001039
SPBio_002631
Spectrum2_001140
Spectrum3_000330
Spectrum4_000267
Spectrum5_000665
Spectrum_000106
UNII-IHS69L0Y4T
cefazolin
cefazolin(usp)
10parecoxibPhase 439198470-84-7
11
DeferoxaminePhase 4, Phase 24570-51-92973
Synonyms:
DF B
DFO
DFOA
DFOM
Deferoxamide B
Deferoxamin
Deferoxamina
 
Deferoxamine B
Deferoxaminum
Deferrioxamine
Deferrioxamine B
Deferrioxamine b
Desferrioxamine
Desferrioxamine B
Déferoxamine
N-Benzoylferrioxamine B
12
s 1 (combination)Phase 4, Phase 2, Phase 1343
Synonyms:
 
Gimeracil / oteracil / tegafur
TS 1
13
CarboplatinPhase 4, Phase 2, Phase 3, Phase 1194241575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
14diureticsPhase 4, Phase 2, Phase 31338
15
CeftriaxonePhase 411273384-59-55479530, 5361919
Synonyms:
(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime), sesquaterhydrate
(6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
104376-79-6
104376-79-6 (di-hydrochloride salt)
73384-59-5
74578-69-1 (di-hydrochloride salt, hemiheptahydrate)
7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
AC-1592
AC1NUIFE
Biotrakson
C06683
C18H18N8O7S3
CEFTRIAXONE SODIUM
CHEBI:29007
CHEMBL161
CID5479530
CTRX
Cefatriaxone
Ceftriaxon
Ceftriaxona
Ceftriaxona [INN-Spanish]
 
Ceftriaxone (INN)
Ceftriaxone (TN)
Ceftriaxone [USAN:JAN]
Ceftriaxone intravenous
Ceftriaxone, Disodium Salt
Ceftriaxone, Disodium Salt, Hemiheptahydrate
Ceftriaxonum
Ceftriaxonum [INN-Latin]
Ceftriazone
D07659
DB01212
DRG-0071
EINECS 277-405-6
LS-150031
Longacef
Longaceph
MolPort-005-933-495
Ro 139904
Ro-13-9904
Ro13-9904
Rocefin
Rocephin
Rocephine
UNII-75J73V1629
ceftriaxone
16
lanreotidePhase 4, Phase 2, Phase 379108736-35-2
Synonyms:
Lanreotide
 
Lanreotide acetate
Somatuline Depot
17
SomatostatinPhase 4, Phase 2, Phase 321238916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
18
MaravirocPhase 4139376348-65-13002977
Synonyms:
376348-65-1
4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide
4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
674782-29-7
AC-558
AC1MHEFQ
CHEBI:537583
CHEMBL1201187
CHEMBL256907
CID3002977
Celsentri
Celsentri(TM)
DB04835
Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide
 
LS-182818
MVC
Maraviroc
Maraviroc [USAN]
PRO 140 & Maraviroc
PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide
Selzentry
Selzentry(TM)
UK 427857
UK-427,857
UK-427,857 maraviroc (MVC)
UK-427857
UNII-MD6P741W8A
exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide
maraviroc
19
PosaconazolePhase 452171228-49-2147912
Synonyms:
1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one
171228-49-2
177571-33-4
4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one
4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
4-[4-[4-[4-[[(5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
AC-1350
AC1L3W34
AC1LAHLQ
AKOS005145917
CHEBI:434337
CHEMBL1397
CHEMBL371938
CHEMBL371939
CID10532764
CID11520437
CID11542142
CID147912
CID468595
D02555
 
DB01263
HSDB 7421
LS-186118
LS-186988
LS-187630
MolPort-006-666-426
Noxafil
Noxafil (TN)
Noxafil, Posaconazole
Posaconazole
Posaconazole (USAN/INN)
Posaconazole SP
Posaconazole [USAN:INN:BAN]
Posaconazole in combination with MGCD290
S1257_Selleck
SCH-56592
SCH56592
Sch 56592
Spriafil
UNII-6TK1G07BHZ
X2N
posaconazole
20
MiconazolePhase 4, Phase 2, Phase 3, Phase 1, Phase 0357322916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
21
EntecavirPhase 4, Phase 2, Phase 3, Phase 1176142217-69-4153941
Synonyms:
142217-69-4
2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one--water (1/1)
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one
209216-23-9
6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]
9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)guanine monohydrate
AB1004838
AC-1593
AC1L4BEC
Anhydrous entecavir
BMS-200475
Baraclude
Baraclude (TN)
CHEBI:473990
CHEBI:59902
CHEMBL713
CID153941
 
D04008
D07896
DB00442
ETV
Entecavir
Entecavir (INN)
Entecavir (USAN)
Entecavir (anhydrous)
Entecavir anhydrous
Entecavir hydrate
Entecavir hydrate (JAN)
Entecavirum
FT-0083013
MolPort-005-942-963
S2128_Selleck
SBB066120
SQ-34676
TL8000933
ZINC03802690
entecavir monohydrate
22
rituximabPhase 4, Phase 3, Phase 2, Phase 11611174722-31-710201696
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
 
Ig gamma-1 chain C region
MabThera
Mabthera
Rituxan
rituximab
23
PioglitazonePhase 4, Phase 2428111025-46-84829
Synonyms:
(+-)-5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione
(+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione
105355-27-9
111025-46-8
198077-89-3
2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI)
5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione
5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione
5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione
5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione
5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione
AB1004597
AC-1021
AC1L1J1Q
AD 4833
AD-4833
Actos
Actos (TN)
Actost
BRD-A48430263-003-02-4
BSPBio_002723
C07675
C19H20N2O3S
CHEBI:8228
CHEMBL595
CID4829
D08378
DB01132
Duetact
Glustin
HMS2089H14
HS-0047
 
HSDB 7322
I06-0089
KBio2_002103
KBio2_004671
KBio2_007239
KBio3_001943
KBioGR_001619
KBioSS_002103
LS-151327
MolPort-002-508-211
NCGC00163128-01
NCGC00163128-02
Pioglitazona
Pioglitazona [INN-Spanish]
Pioglitazone
Pioglitazone HCl
Pioglitazone Hydrochloride
Pioglitazone [BAN:INN]
Pioglitazone [Ban:Inn]
Pioglitazone [INN:BAN]
Pioglitazonum
Pioglitazonum [INN-Latin]
SPBio_001897
Spectrum2_001679
Spectrum3_001002
Spectrum4_001130
Spectrum5_001480
Spectrum5_002067
Spectrum_001623
U 72107
U 72107A
U-72107
U72,107A
UNII-X4OV71U42S
Zactos
nchembio790-comp10
pioglitazone (INN)
pioglitazone HCl
24insulinPhase 4, Phase 3, Phase 2, Phase 1, Phase 04401
25
Tranexamic AcidPhase 4, Phase 3, Phase 22411197-18-85526
Synonyms:
08455_FLUKA
1197-17-7
1197-18-8
1ceb
3-14-00-00868 (Beilstein Handbook Reference)
4-(Aminomethyl)-Cyclohexanecarboxylic Acid
4-(Aminomethyl)cyclohexanecarboxylic acid
4-(aminomethyl)cyclohexane-1-carboxylic acid
857653_ALDRICH
A0236
AB00052260
AB1003647
AC-4687
AC1L1KJH
AC1Q50F3
AC1Q546D
AC1Q5U04
ALBB-006013
AMCA
AMCHA
AMH
AR-1F6595
Acide tranexamique
Acide tranexamique [INN-French]
Acido tranexamico
Acido tranexamico [INN-Spanish]
Acidum tranexamicum
Acidum tranexamicum [INN-Latin]
Amikapron
Amstat
Anvitoff
BAY 3517
BPBio1_000069
BRN 2207452
BSPBio_000061
BSPBio_002837
CAS-1197-18-8
CHEBI:48669
CHEMBL292500
CHEMBL877
CID5526
CL 65336
CL-65336
Carxamin
Cyclocapron
Cyklokapron
Cyklokapron (TN)
D01136
DB00302
DV 79
DV-79
DV79
DivK1c_000655
EINECS 214-818-2
Emorhalt
Exacyl
Frenolyse
HMS1568D03
HMS1921F08
HMS2092P03
HMS502A17
Hexapromin
Hexatron
I04-0993
IDI1_000655
KABI 2161
KBio1_000655
KBio2_001871
KBio2_004439
KBio2_007007
KBio3_002337
KBioGR_000511
 
KBioSS_001871
LS-56611
LS-56612
LT00159441
Mastop
MolPort-001-792-390
MolPort-002-512-008
NCGC00016569-01
NCGC00016569-02
NCGC00016569-03
NCGC00094944-01
NCGC00094944-02
NINDS_000655
NSC 291305
NSC291305
Oprea1_786414
Prestwick0_000171
Prestwick1_000171
Prestwick2_000171
Prestwick3_000171
Prestwick_476
RP 18,429
Rikavarin
Rikavarin (TN)
Rikavarin-S
SPBio_000689
SPBio_001982
SPECTRUM1502026
STK503668
STOCK1N-16183
Spectrum2_000655
Spectrum3_001189
Spectrum4_000046
Spectrum5_001258
Spectrum_001391
Spiramin
Tamcha
Tranex
Tranexamate
Tranexamic acid (JP15/USAN/INN)
Tranexamic acid [USAN:INN:BAN:JAN]
Tranexamic acid cis-form
Tranexamsaeure
Tranexan
Tranexmic acid
Tranhexamic acid
Trans AMCHA
Trans-1-(Aminomethyl)cyclohexane-4-carboxylic acid
Trans-4-(Aminomethyl)-1-cyclohexanecarboxylic acid
Trans-p-(Aminomethyl)cyclohexanecarboxylic
Transamin
Transamin (TN)
Transamlon
Trasamlon
UNII-6T84R30KC1
Ugurol
WLN: L6TJ AVQ D1Z -T
cis-4-(Aminomethyl)cyclohexanecarboxylic acid
cis-4-Aminomethylcyclohexane-1-carboxylic acid
cis-AMCHA
t-AMCHA
tranexamic acid
tranexmic acid
trans-1-Aminomethylcyclohexane-4-carboxylic acid
trans-4-(Aminomethyl)cyclohexane-1-carboxylic acid
trans-4-(Aminomethyl)cyclohexane-carboxylic acid
trans-4-(Aminomethyl)cyclohexanecarboxylic acid
trans-4-(Aminomethyl)cyclohexanecarboxylic acid ester
trans-4-Aminomethylcyclohexane-1-carboxylic acid
trans-4-aminomethylcyclohexane-1-carboxylic acid
trans-Amcha
trans-Tranexamic acid
trans-p-(Aminomethyl)cyclohexanecarboxylic acid
26
DeferasiroxPhase 4, Phase 3, Phase 287201530-41-85493381
Synonyms:
Deferasiroxum
Deferasiroxum [inn-latin]
 
Exjade
ICL 670
ICL 670a
deferasirox
27
EverolimusPhase 4, Phase 2, Phase 3, Phase 1, Phase 01863159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
28
Mycophenolate mofetilPhase 4, Phase 3, Phase 2, Phase 1919128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
29TegafurPhase 4, Phase 28417902-23-7
30
cetuximabPhase 4, Phase 3, Phase 2, Phase 1, Phase 0720205923-56-456842117, 2333
Synonyms:
205923-56-4
Anti EGFR
Cetuximab
Cetuximab (USAN/INN)
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
 
Cetuximabum
Cétuximab
D03455
Erbitux
Erbitux (TN)
IMC-C225
Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer
cetuximab
31
Ursodeoxycholic acidPhase 4, Phase 283128-13-231401
Synonyms:
(3a,5b,7b)-3,7-dihydroxy-cholan-24-oate
(3a,5b,7b)-3,7-dihydroxy-cholan-24-oic acid
(3a,5b,7b)-3,7-dihydroxycholan-24-oic acid
(3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid
(3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid
(3α,5β,7β)-3,7-dihydroxycholan-24-oic acid
(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
128-13-2
17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol
3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid
3,7-Dihydroxycholan-24-oic acid
3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid
3-alpha,7-beta-Dihydroxycholanic acid
3-alpha,7-beta-Dioxycholanic acid
3a,7b-Dihydroxy-5b-cholan-24-oate
3a,7b-Dihydroxy-5b-cholan-24-oic acid
3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid
3alpha,7beta-Dihydroxy-5beta-cholanic acid
4-10-00-01604 (Beilstein Handbook Reference)
50809-41-1
5beta-Cholan-24-oic acid-3alpha,7beta-diol
5beta-Cholanic Acid-3alpha,7beta-diol
7-beta-Hydroxylithocholic acid
7beta-Hydroxylithocholic acid
80225-86-1
AB00513977
AC-18919
AC-2081
AC1L1LJH
Acide ursodesoxycholique
Acide ursodesoxycholique [INN-French]
Acido ursodeossicolico
Acido ursodeossicolico [Italian]
Acido ursodeoxicolico
Acido ursodeoxicolico [INN-Spanish]
Acidum ursodeoxycholicum
Acidum ursodeoxycholicum [INN-Latin]
Actigall
Actigall (TN)
Antigall
Arsacol
BB_NC-2372
BPBio1_001052
BRN 3219888
BSPBio_000956
C07880
C24H40O4
CCRIS 5502
CHEBI:9907
CHEMBL1551
CHEMBL73390
CID11516715
CID31401
CPD-10534
CPD000058403
Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)- (9CI)
Cholit-ursan
D00734
DB01586
Delursan
Deoxyursocholic Acid
Destolit
Deursil
Dom-ursodiol c
EINECS 204-879-3
HMS1570P18
 
ISO-URSODEOXYCHOLIC ACID
IU5
LMST04010033
LS-53033
Litursol
Lyeton
MLS000028461
MLS001066373
MolPort-001-794-630
MolPort-005-932-884
NCGC00179363-01
NCI60_028904
NSC 657950
NSC 683769
PHL-ursodiol c
PMS-ursodiol c
Peptarom
Prestwick0_000958
Prestwick1_000958
Prestwick2_000958
Prestwick3_000958
S1643_Selleck
SAM002264653
SMP2_000012
SMR000058403
SPBio_003105
Sodium Ursodeoxycholate
Solutrat
U-9000
U0030
U5127_SIGMA
UDCA
UDCS
UNII-724L30Y2QR
URSODEOXYCHOLIC ACID
UrSO
Urosdesoxycholate
Urosdesoxycholic acid
Urosiol
Ursacholic Acid
Ursacol
Urso
Urso (TN)
Urso 250
Urso DS
Urso Forte
Ursobilin
Ursochol
Ursodamor
Ursodeoxy cholic acid
Ursodeoxycholate
Ursodeoxycholic acid
Ursodeoxycholic acid (JP15/INN)
Ursodeoxycholic acid, UDCA, Ursosan, Ursofalk, Urso Forte, Udiliv, Ursodiol
Ursodeoxycholicacid
Ursodesoxycholic acid
Ursodexycholate
Ursodexycholic Acid
Ursodexycholic acid
Ursodiol
Ursodiol (USP)
Ursodiol [USAN]
Ursofalk
Ursolvan
Ursosan
chenodeoxycholic acid
ursodeoxycholate
ursodiol
32
ZincPhase 4, Phase 221547440-66-632051, 23994
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
33
sofosbuvirPhase 4, Phase 3, Phase 22121190307-88-045375808
Synonyms:
 
S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4- dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)- (phenoxy)phosphorylamino)propanoate
SOVALDI
34
IrinotecanPhase 4, Phase 3, Phase 2, Phase 1106297682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
35
LevoleucovorinPhase 4, Phase 3, Phase 2, Phase 169668538-85-2
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-5-formyltetrahydrofolic acid
(6S)-Folinic acid
(6S)-Leucovorin
 
(S)-Leucovorin
Citrovorum factor
L-Folinic acid
Levofolene
Levofolinic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
36
CapecitabinePhase 4, Phase 3, Phase 2, Phase 11257154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
37
Citric AcidPhase 4, Phase 3, Phase 2, Phase 1106377-92-9311
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
Chemfill
Citraclean
 
Citrate
Citretten
Citric acid
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
38
trastuzumabPhase 4, Phase 2, Phase 1751180288-69-19903
Synonyms:
180288-69-1
Anti HER2
Anti-erbB2 Monoclonal Antibody
D03257
HER2 Monoclonal Antibody
Herceptin
 
Herceptin (TN)
Ig gamma-1 chain C region
Trastuzumab
Trastuzumab (INN)
Trastuzumab (genetical recombination)
Trastuzumab (genetical recombination) (JAN)
trastuzumab
39
MentholPhase 4, Phase 3, Phase 2, Phase 121842216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
40
PravastatinPhase 4, Phase 3, Phase 214781093-37-054687
Synonyms:
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid
(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid
3beta-Hydroxycompactin
81093-37-0
81131-70-6 (hydrochloride salt)
AC1L1HJL
AC1Q5T3M
BIDD:GT0773
BRD-K60511616-236-01-4
C01844
C23H36O7
CCRIS 7557
CHEMBL1144
CID54687
Compactin
D08410
DB00175
Elisor
Eptastatin
FT-0082682
KS-5015
LS-94713
Lipostat
Mevalothin
Mevalotin
Mevastatin
Mevinolin
 
Oliprevin
Pravachol
Pravaselect
Pravastatin (INN)
Pravastatin Sodium
Pravastatin Sodium Salt
Pravastatin [INN:BAN]
Pravastatin acid
Pravastatin sodium
Pravastatin tert-Octylamine Salt
Pravastatina
Pravastatina [Spanish]
Pravastatine
Pravastatine [French]
Pravastatinum
Pravastatinum [Latin]
Pravator
Pravator (TN)
RMS-431
SQ-31,000
Selectin
Selektine
Selipran
UNII-KXO2KT9N0G
Vasten
nchembio.301-comp7
nchembio790-comp15
pravastatin
pravastatina
pravastatine
pravastatinum
41
WarfarinPhase 4, Phase 344181-81-26691, 54678486
Synonyms:
(-)-Warfarin
(S)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone
(S)-Warfarin
(phenyl-1 acetyl-2 ethyl) 3-hydroxy-4 coumarin
(phenyl-1 acetyl-2 ethyl) 3-hydroxy-4 coumarine
1-(4'-Hydroxy-3'-coumarinyl)-1-phenyl-3-butanone
200 Coumarin
200 coumarin
3-(1'-Phenyl-2'-acetylethyl)-4-hydroxycoumarin
3-(Acetonylbenzyl)-4-hydroxycoumarin
3-(alpha-Acetonylbenzyl)-4-hydroxycoumarin
3-(alpha-Phenyl-beta-acetylaethyl)-4-hydroxycumarin
3-(alpha-Phenyl-beta-acetylethyl)-4-hydroxycoumarin
4-Hydroxy-3- (3-oxo-1-fenyl-butyl) cumarine
4-Hydroxy-3- (3-oxo-1-phenyl-butyl)-cumarin
4-Hydroxy-3-(3-oxo-1-fenyl-butyl) cumarine
4-Hydroxy-3-(3-oxo-1-phenyl-butyl)-cumarin
4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one
4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin
4-Idrossi-3- (3-oxo-)-fenil-butil)-cumarine
4-Idrossi-3-(3-oxo-)-fenil-butil)-cumarine
4-Idrossi-3-(3-oxo-1-fenil-butil)-cumarine
45706_FLUKA
45706_RIEDEL
4oh-coumarin deriv.
5543-56-6
5543-57-7
81-81-2
A2250_FLUKA
A2250_SIGMA
AC-15978
AC1L1N37
AC1Q6AN3
AR-1E2310
Arab Rat Death
Arab rat death
Arab rat deth
Athrombin
Athrombin-K
Athrombin-k
Athrombine-K
Athrombine-k
BRD-A24514565-001-02-2
BRD-A24514565-236-01-6
BRN 1293536
BSPBio_002026
Bio-0586
Brumolin
C01541
C19H16O4
CBDivE_002127
CBDivE_013236
CBKinase1_000192
CBKinase1_012592
CHEBI:10033
CHEMBL1464
CID6691
CO-Rax
Caswell No. 903
Choice
Choice (TN)
Co-Rax
Co-rax
Compound 42
Coumadin
Coumadin Tabs
Coumafen
Coumafene
Coumafene [French]
Coumaphen
Coumaphene
Coumarins
Coumefene
Cov-R-Tox
Cov-R-tox
D-Con
D08682
DB00682
DL-3-(alpha-acetonylbenzyl)-4-hydroxycoumarin
Dethmor
Dethnel
Dicusat E
Dicusat e
DivK1c_000444
EINECS 201-377-6
EINECS 226-907-3
EPA Pesticide Chemical Code 086002
Eastern states duocide
Fasco fascrat powder
Frass-Ratron
Frass-ratron
HMS1921K07
HMS2092C20
HMS501G06
HSDB 1786
I14-0958
IDI1_000444
Jantoven
KBio1_000444
KBio2_000674
KBio2_003242
KBio2_005810
KBio3_001526
KBioGR_000901
KBioSS_000674
Killgerm sewarin p
Kumader
Kumadu
Kumatox
Kypfarin
LS-55083
Latka 42
Latka 42 [Czech]
Liqua-tox
MLS001304042
Maag Rattentod Cum
Maag rattentod cum
Mar-Frin
Mar-frin
Marevan
Martin'S mar-frin
Martin's mar-frin
 
Maveran
MolPort-001-787-822
Mouse pak
NCGC00094810-01
NCGC00094810-02
NCGC00159398-03
NCGC00178855-01
NINDS_000444
NSC 59813
NSC59813
PS104_SUPELCO
Panwarfin
Place-Pax
Place-pax
Prothromadin
RAX
RCR grey squirrel killer concentrate
RCRA waste no. P001
Rat & mice bait
Rat and mice bait
Rat-B-gon
Rat-Gard
Rat-Kill
Rat-Mix
Rat-O-cide #2
Rat-O-cide no. 2
Rat-Ola
Rat-Trol
Rat-a-way
Rat-alpha-way
Rat-b-gon
Rat-beta-gon
Rat-gard
Rat-kill
Rat-mix
Rat-o-cide #2
Rat-ola
Rat-trol
Ratorex
Ratox
Ratoxin
Ratron
Ratron G
Ratron g
Rats-no-more
Ratten-Koederrohr
Ratten-koederrohr
Rattenstreupulver Neu Schacht
Rattenstreupulver neu schacht
Rattenstreupulver new schacht
Rattentraenke
Rattunal
Rcra waste number P001
Ro-Deth
Ro-deth
Rodafarin
Rodafarin C
Rodafarin c
Rodex
Rodex blox
Rosex
Rough & ready mouse mix
Rough and ready mouse mix
SMP1_000316
SMR000718754
SPBio_000870
SPECTRUM1500613
STK364490
Sakarat
Sewarin
Sofarin
Solfarin
Sorexa Plus
Sorexa plus
Spectrum2_000935
Spectrum3_000583
Spectrum4_000381
Spectrum5_001751
Spectrum_000194
Spray-trol brand roden-trol
Temus W
Temus w
Tintorane
Tox-Hid
Tox-hid
Twin light rat away
UNII-5Q7ZVV76EI
Vampirinip II
Vampirinip III
Vampirinip iii
W.A.R.F. 42
WARF compound 42
WLN: T66 BOVJ DYR&1V1 EQ
Waran
Warf 10
Warf 42
Warfarat
Warfarin (INN)
Warfarin (and salts of)
Warfarin Plus
Warfarin Q
Warfarin [BSI:ISO]
Warfarin [INN:BAN]
Warfarin plus
Warfarin plus [discontinued]
Warfarin sodium
Warfarin titrated to an INR of 2.5-3.0
Warfarin(R)
Warfarina
Warfarina [INN-Spanish]
Warfarine
Warfarine [INN-French]
Warfarine [ISO-French]
Warfarinum
Warfarinum [INN-Latin]
Warficide
Warfilone
Zoocoumarin
Zoocoumarin [Netherlands and USSR]
Zoocoumarin [Russian]
delta-Con
nchembio.307-comp19
rac-Warfarin
warfarin
42
CelecoxibPhase 4, Phase 1, Phase 2427169590-42-52662
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC-4228
AC1L1E6K
AI-525
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
CPD000550473
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
Celecoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
Célécoxib
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
KBio2_000912
 
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
MLS001165684
MLS001195656
MLS001304708
Medicoxib
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC-58635
SC58635
SMR000550473
SPBio_001512
SPECTRUM1503678
Solexa
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
Spectrum_000432
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM-177
YM177
ZINC02570895
cMAP_000027
celecoxib
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
43calcium channel blockersPhase 41889
44
TacrolimusPhase 4, Phase 3, Phase 2, Phase 1, Phase 01058104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
45
sirolimusPhase 4, Phase 2, Phase 3, Phase 1, Phase 0186353123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
46
Mycophenolic acidPhase 4, Phase 3, Phase 2, Phase 191924280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
47
AspirinPhase 4, Phase 3, Phase 2107450-78-22244
Synonyms:
11126-35-5
11126-37-7
1oxr
2-(ACETYLOXY)benzoic acid
2-(Acetyloxy)benzoate
2-(Acetyloxy)benzoic acid
2-Acetoxybenzenecarboxylic acid
2-Acetoxybenzoate
2-Acetoxybenzoic acid
2-Carboxyphenyl acetate
2349-94-2
26914-13-6
50-78-2
8-hour Bayer
98201-60-6
A 5376
A.S.A
A.S.A.
A.S.A. Empirin
A.S.A. empirin
A2093_SIGMA
A3160_SIGMA
A5376_SIGMA
A6810_SIGMA
AB1003266
AC 5230
AC1L1D8U
AC1Q1LA0
ACETYLSALICYLIC ACID
AI3-02956
AIN
AKOS000118884
ASA
Acenterine
Acesal
Acetal
Acetard
Aceticyl
Acetilsalicilico
Acetilum acidulatum
Acetisal
Acetol
Acetonyl
Acetophen
Acetosal
Acetosalic acid
Acetosalin
Acetoxybenzoic acid
Acetylin
Acetylsal
Acetylsalicylate
Acetylsalicylic acid
Acetylsalicylsaeure
Acetylsalicylsaure
Acetylsalycilic acid
Acetyonyl
Acetysal
Acetysalicylic acid
Acide 2-(acetyloxy)benzoique
Acide acetylsalicylique
Acide acétylsalicylique
Acido O-acetil-benzoico
Acido acetilsalicilico
Acidum acetylsalicylicum
Acimetten
Acisal
Acylpyrin
Adiro
Aloxiprimum
Asacard
Asagran
Asatard
Ascoden-30
Aspalon
Aspec
Aspergum
Aspir-Mox
Aspirdrops
Aspirin
Aspirin (JP15/USP)
Aspirin [BAN:JAN]
Aspirina 03
Aspirine
Asprin
Aspro
Aspro Clear
Asteric
Azetylsalizylsaeure
Azetylsalizylsäure
BIDD:GT0118
BRN 0779271
Bay-e-4465
Bayer
Bayer Aspirin 8 Hour
Bayer Buffered
Bayer Extra Strength Aspirin For Migraine Pain
Bayer Plus
Benaspir
Bi-prin
Bialpirina
Bialpirinia
Bufferin
C01405
CCRIS 3243
CHEBI:15365
CHEMBL25
CID2244
Caprin
Cardioaspirin
Cardioaspirina
Cemirit
Claradin
Clariprin
Colfarit
Contrheuma retard
Coricidin
Crystar
D00109
D001241
DB00945
Decaten
Delgesic
Dispril
DivK1c_000555
Dolean pH 8
Duramax
ECM
EINECS 200-064-1
EU-0100038
Easprin
Easprin (TN)
Ecolen
Ecotrin
Empirin
Empirin with Codeine
Endosprin
Endydol
 
Entericin
Enterophen
Enterosarein
Enterosarine
Entrophen
Extren
Globentyl
Globoid
HMS1920E13
HMS2090G03
HMS2091K13
HMS501L17
HSDB 652
Helicon
I14-7505
IDI1_000555
Idragin
Istopirin
KBio1_000555
KBio2_001725
KBio2_002271
KBio2_004293
KBio2_004839
KBio2_006861
KBio2_007407
KBio3_002149
KBio3_002751
KBioGR_000398
KBioGR_002271
KBioSS_001725
KBioSS_002272
Kapsazal
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
LS-143
Levius
Lopac-A-5376
Lopac0_000038
MLS001055329
MLS001066332
MLS001336045
MLS001336046
Magnecyl
Measurin
Medisyl
Micristin
MolPort-000-871-622
NCGC00015067-01
NCGC00015067-04
NCGC00015067-09
NCGC00090977-01
NCGC00090977-02
NCGC00090977-03
NCGC00090977-04
NCGC00090977-05
NCGC00090977-06
NCGC00090977-07
NCI60_002222
NINDS_000555
NSC 27223
NSC27223
NSC406186
Neuronika
Novid
Nu-seals
Nu-seals aspirin
O-(Acetyloxy)benzoate
O-(Acetyloxy)benzoic acid
O-Acetoxybenzoate
O-Acetoxybenzoic acid
O-Acetylsalicylic acid
O-Carboxyphenyl acetate
O-accetylsalicylic acid
O-acetylsalicylic acid
PL-2200
Persistin
Pharmacin
Pirseal
Polopirin
Polopiryna
Premaspin
R16CO5Y76E [UNII]
Rheumin tabletten
Rheumintabletten
Rhodine
Rhonal
Ronal
S-211
SMR000059138
SP 189
SPBio_001838
SPECTRUM1500130
ST075414
Salacetin
Salcetogen
Saletin
Salicylic acid acetate
Salicylic acid, acetate
Salospir
Solfrin
Solprin
Solprin acid
Solpyron
Solupsan
Spectrum2_001899
Spectrum3_001295
Spectrum4_000099
Spectrum5_000740
Spectrum_001245
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
Supac
Tasprin
Temperal
Toldex
Triaminicin
Triple-sal
UNII R16CO5Y76E
UNII-R16CO5Y76E
UNII=R16CO5Y76E
UNM-0000306102
Vanquish
WLN: QVR BOV1
XAXA
Xaxa
Yasta
ZORprin
aspirin
cMAP_000006
component of Midol
component of Synirin
nchem.859-comp6
o-Acetoxybenzoic acid
o-Carboxyphenyl acetate
o-acetoxybenzoic acid
o-carboxyphenyl acetate
ácido acetilsalicílico
48calcium heparinPhase 4, Phase 2, Phase 3, Phase 1, Phase 0779
49NadroparinPhase 4, Phase 2, Phase 3329041-08-1
50
HeparinPhase 4, Phase 2, Phase 3, Phase 1, Phase 07799005-49-6772, 46507594
Synonyms:
101921-26-0
102-94-3
102785-31-9
104521-37-1
11078-24-3
11129-39-8
12656-11-0
2-o-sulfohexopyranuronosyl-(1->4)-2-deoxy-3-o-sulfo-2-(sulfoamino)hexopyranosyl-(1->4)-2-o-sulfohexopyranuronosyl-(1->4)-2-acetamido-2-deoxy-6-o-sulfohexopyranose
37324-73-5
6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid
9041-08-1
9045-22-1
9075-96-1
913079-23-9
91449-79-5
AC1L19ZN
AC1L1ROY
ALFA 87-120
ALFA 87-163
ALFA 87-198
ALFA 87-81
ALFA 88-247
AR-1E4539
Allocinnamic acid
Ardeparin
Ardeparin sodium
Arteven
Bemiparin
Bemiparin sodium
CID772
CID8784
CY 216
Calciparine
Certoparin
Clexane
Clivarin
Clivarine
Cy 222
D006495
D017984
DB00407
DB01225
Dalteparin
Dalteparin sodium
Depo-Heparin
EINECS 232-681-7
EMT 966
EMT 967
EMT-966
EMT-967
EMT966
EMT967
Enoxaparin
Enoxaparin sodium
Enoxaparine
Eparina
Eparina [DCIT]
FR 860
Fluxum
Fragmin A
Fragmin B
Fragmin IV
Fraxiparin
H 2149
HSDB 3094
Hed-heparin
Hep Flush Kit in plastic container
Hep-Lock
Hep-Lock U/P
Hep-lock
Heparin
Heparin CY 216
Heparin Lock Flush
Heparin Lock Flush in plastic container
Heparin Lock Flush preservative free
Heparin Lock Flush preservative free in plastic container
Heparin Sodium
Heparin natrium
Heparin sodium
Heparin sodium 1,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 1,000 units in dextrose 5% in plastic container
Heparin sodium 1,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 10,000 units in dextrose 5%
Heparin sodium 10,000 units in dextrose 5% in plastic container
Heparin sodium 10,000 units in sodium chloride 0.45%
Heparin sodium 10,000 units in sodium chloride 0.9%
Heparin sodium 12,500 units in dextrose 5%
Heparin sodium 12,500 units in dextrose 5% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.45% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.9%
Heparin sodium 2,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 2,000 units in dextrose 5% in plastic container
Heparin sodium 2,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 20,000 units and dextrose 5% in plastic container
Heparin sodium 20,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units and dextrose 5% in plastic container
 
Heparin sodium 25,000 units in dextrose 5%
Heparin sodium 25,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.45% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.9%
Heparin sodium 25,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units in dextrose 5% in plastic container
Heparin sodium 5,000 units in sodium chloride 0.45%
Heparin sodium 5,000 units in sodium chloride 0.9%
Heparin sodium 5,000 units in sodium chloride 0.9% in plastic container
Heparin sodium in plastic container
Heparin sodium preservative Free
Heparin sulfate
Heparin sulphate
Heparin, Low Molecular Weight
Heparin, Low-Molecular-Weight
Heparin, sodium salt
Heparina
Heparina [INN-Spanish]
Heparinate
Heparine
Heparine [INN-French]
Heparinic acid
Heparinsodiumsalt
Heparinum
Heparinum [INN-Latin]
Heparinum natricum
Hepathrom
Hepflush-10
Inno-Hep
Innohep
Isocinnamic acid
KB 101
Kabi 2165
LHN 1
LMWH
Lioton 1000
Lipo-hepin
Liquaemin
Liquaemin Lock Flush
Liquaemin Sodium
Liquaemin sodium preservative free
Liquemin
Logiparin
Lovenox
Lovenox HP
Low Molecular Weight Heparin
Low molecular weight heparin
Low molecular weight heparin sodium
Low-Molecular-Weight Heparin
Minolteparin sodium
MolPort-003-760-257
Multiparin
NSC174025
Nadroparin
Nadroparine
Novoheparin
OP 386
OP 622
Octaparin
PK 10,169
PK-10,169
PK-10169
PK10,169
PK10169
Pabyrin
Panheprin
Parnaparin
Parnaparin sodium
Parvoparin
Pularin
Reviparin
Reviparin sodium
Ro 11
Sandoparin
Sodium acid heparin
Sodium heparin
Sodium heparinate
Subeparin
Sublingula
Thromboliquine
Tinzaparin
Tinzaparin sodium
Triofiban
UNII-12M44VTJ7B
UNII-3S182ET3UA
UNII-E47C0NF7LV
UNII-T2410KM04A
UNII-ZZ45AB24CA
Unfractionated heparin
Vetren
Vitrum AB
WY 90493RD
alpha-Heparin
cis-.beta.-Carboxystyrene
cis-Cinnamic acid
enoxaparin
heparin

Interventional clinical trials:

(show top 50)    (show all 3173)
idNameStatusNCT IDPhase
1Drug-eluting Bead in Hepatocellular CarcinomaCompletedNCT01332669Phase 4
2Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive DiagnosisCompletedNCT01575574Phase 4
3Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor ThrombosisCompletedNCT00646100Phase 4
4Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous ThrombusCompletedNCT01600196Phase 4
5Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese PatientsCompletedNCT01098760Phase 4
6The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC)CompletedNCT00397540Phase 4
7Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).CompletedNCT01798160Phase 4
8Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular CarcinomaCompletedNCT00829465Phase 4
9Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)CompletedNCT01203787Phase 4
10Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCCCompletedNCT00375661Phase 4
11Hepatic Xenetix-CT PerfusionCompletedNCT01639703Phase 4
12Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular CarcinomaCompletedNCT00630084Phase 4
13Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma TherapyCompletedNCT00575523Phase 4
14Preoperative Transarterial Chemoembolization for Resectable HCC With Portal Venous InvasionCompletedNCT01952353Phase 4
15Traditional (Traditional Chemoembolization) TACE Versus Microsphere TACECompletedNCT00936689Phase 4
16A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCCCompletedNCT01263002Phase 4
17Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological TumorsCompletedNCT00168987Phase 4
18Qidong Hepatitis B Intervention StudyCompletedNCT00222664Phase 4
19Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C:An Open-label Control Study in ChinaCompletedNCT02898922Phase 4
20Prospective Anti-Hepatitis C Virus (Anti-HCV) Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian EthnicityCompletedNCT00957866Phase 4
21Omega-3 Fatty Acid-Based Parenteral Nutrition Improves Postoperative Recovery for Cirrhotic Patients With Liver CancerCompletedNCT02321202Phase 4
22Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit SmokingCompletedNCT00365508Phase 4
23The Efficacy of Chlorhexidine Gluconate Pre - Disinfection Scrubbing in Preventing Surgical Site Infections for Hepatectomy PatientsCompletedNCT01782573Phase 4
24Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal TumoursCompletedNCT02016391Phase 4
25Effects of Dexmedetomidine During IRE Procedures for Solid TumoursCompletedNCT02044224Phase 4
26Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3CompletedNCT00056862Phase 4
27Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis CCompletedNCT00203606Phase 4
28Long-Term Lamivudine Therapy for Chronic Hepatitis BCompletedNCT00120354Phase 4
29Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.CompletedNCT01195181Phase 4
30Long-Term Therapy With Ribavirin for Chronic Hepatitis CCompletedNCT00001854Phase 4
31Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal CancerCompletedNCT00869271Phase 4
32I Phase Surgery Versus Staged Surgery for Synchronous Liver Metastasis of Colorectal CancerCompletedNCT00677586Phase 4
33Prevalence of Colon Cancer in Pyogenic Liver AbscessCompletedNCT02032914Phase 4
34A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal CancerCompletedNCT01695772Phase 4
35Liver Safety Under Upfront Arimidex vs TamoxifenCompletedNCT00537771Phase 4
36Health Economic Evaluation of Primovist-enhanced Liver MRICompletedNCT00764621Phase 4
37MRI Substudy; Metabolic Changes Due to Iatrogenic HypogonadismCompletedNCT02102646Phase 4
38Penetration of Moxifloxacin Into Liver Tissue of Patients Undergoing Liver Resection.CompletedNCT01302951Phase 4
39Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative TherapyCompletedNCT00526331Phase 4
40Antinociceptive Modalities on Ischemia Reperfusion InjuryCompletedNCT01932918Phase 4
41Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 CyclesCompletedNCT00868816Phase 4
42Standard and Immunostimulating Enteral Nutrition in Surgical PatientsCompletedNCT00576940Phase 4
43Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)CompletedNCT01172548Phase 4
44Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver FailureCompletedNCT01074645Phase 4
45A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface AreaCompletedNCT02372357Phase 4
46EuroSIDA As An External Comparator To MOTIVATE TrialsCompletedNCT01329783Phase 4
47An Observational Study of Chinese Multiple Myeloma Patients Treated With VelcadeCompletedNCT01675245Phase 4
48Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic HepatitisCompletedNCT02331589Phase 4
49A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.CompletedNCT01861717Phase 4
50Kaiser Permanente HIV Cohort StudyCompletedNCT01339403Phase 4

Search NIH Clinical Center for Hepatocellular Carcinoma

Inferred drug relations via UMLS66/NDF-RT44:

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatocellular Carcinoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes, PMIDs: 24329789, 19342963, 23904171, 21498393, 22996367, 19304471, 22555974, 15800326, 23650429, 21325070, 24218514, 8170938, 12242449


Cochrane evidence based reviews: liver neoplasms

Genetic Tests for Hepatocellular Carcinoma

About this section

Genetic tests related to Hepatocellular Carcinoma:

id Genetic test Affiliating Genes
1 Hepatocellular Carcinoma25
2 Neoplasm of the Liver25

Anatomical Context for Hepatocellular Carcinoma

About this section

MalaCards organs/tissues related to Hepatocellular Carcinoma:

34
Liver, Breast, Lung, T cells, Prostate, Endothelial, Colon

FMA organs/tissues related to Hepatocellular Carcinoma:

17
The liver

Animal Models for Hepatocellular Carcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Hepatocellular Carcinoma:

39 (show all 17)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538411.7APC, AXIN1, CASP8, CTNNB1, FAH, GLUL
2MP:000537011.6AFP, APC, CASP8, CTNNB1, FAH, FGL1
3MP:001076811.6AFP, APC, AXIN1, CASP8, CTNNB1, FAH
4MP:000537811.5APC, AXIN1, CASP8, CTNNB1, FAH, FGL1
5MP:000538711.5APC, CASP8, CTNNB1, FAH, GPC3, MET
6MP:000538011.4APC, AXIN1, CASP8, CTNNB1, GPC3, IGF2R
7MP:000200611.4AFP, APC, CASP8, CTNNB1, FAH, MET
8MP:000538211.4APC, AXIN1, CTNNB1, GPC3, IGF2R, MET
9MP:000538811.3AXIN1, CASP8, CTNNB1, GPC3, IGF2R, MET
10MP:000538511.3APC, AXIN1, CASP8, CTNNB1, GPC3, IGF2R
11MP:000537611.3AFP, APC, CASP8, CTNNB1, FAH, FGL1
12MP:000537911.3AFP, APC, CASP8, CTNNB1, FAH, IGF2R
13MP:000538111.3APC, AXIN1, CTNNB1, GPC3, MET, MTUS1
14MP:000536711.3APC, AXIN1, CASP8, CTNNB1, FAH, GPC3
15MP:000538611.2AFP, APC, AXIN1, CTNNB1, FGL1, GLUL
16MP:000537111.0APC, AXIN1, CTNNB1, GPC3, IGF2R, MET

Publications for Hepatocellular Carcinoma

About this section

Articles related to Hepatocellular Carcinoma:

(show top 50)    (show all 8542)
idTitleAuthorsYear
1
MicroRNA-708 is downregulated in hepatocellular carcinoma and suppresses tumor invasion and migration. (26211597)
2015
2
Prostate tumor overexpressed 1 is a novel prognostic marker for hepatocellular carcinoma progression and overall patient survival. (25634174)
2015
3
Expression of carbonic anhydrase 9 is a novel prognostic marker in resectable hepatocellular carcinoma. (25577552)
2015
4
Atypical Presentation of Hepatocellular Carcinoma Mimicking a Gastric Hepatoid Adenocarcinoma: A Case Report. (26166099)
2015
5
Overexpression of Tyro3 and its implications on hepatocellular carcinoma progression. (26573872)
2015
6
MiR-511 inhibits growth and metastasis of human hepatocellular carcinoma cells by targeting PIK3R3. (25608840)
2015
7
miR-139 regulates the proliferation and invasion of hepatocellular carcinoma through the WNT/TCF-4 pathway. (24190507)
2014
8
Autophagic LC3B overexpression correlates with malignant progression and predicts a poor prognosis in hepatocellular carcinoma. (25256671)
2014
9
Rpb3 promotes hepatocellular carcinoma through its N-terminus. (25211001)
2014
10
Relationship between RUNX3 methylation and hepatocellular carcinoma in Asian populations: a systematic review. (25061743)
2014
11
Low expression of PAI-2 as a novel marker of portal vein tumor thrombosis and poor prognosis in hepatocellular carcinoma. (23188538)
2013
12
Modification of sialylation mediates the invasive properties and chemosensitivity of human hepatocellular carcinoma. (24255131)
2013
13
Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib. (23914915)
2013
14
Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma. (24387824)
2013
15
Significant association between XRCC3 C241T polymorphism and increased risk of hepatocellular carcinoma: a meta-analysis. (23873110)
2013
16
Expression of FOXJ1 in hepatocellular carcinoma: correlation with patients' prognosis and tumor cell proliferation. (22488567)
2013
17
Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma. (23819582)
2013
18
The effect of alkaline phosphatase and intrahepatic metastases in large hepatocellular carcinoma. (23432910)
2013
19
Loss of p57 expression and RhoA overexpression are associated with poor survival of patients with hepatocellular carcinoma. (23842948)
2013
20
Hepatocellular carcinoma as unusual cause for paraplegia. (22965954)
2012
21
Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25(-) FOXP3(-) T cells. (22419479)
2012
22
Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma. (22515642)
2012
23
Underexpressed microRNA-199b-5p targets hypoxia-inducible factor-1I+ in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients. (21557766)
2011
24
Liver stiffness measured by transient elastography is a predictor of hepatocellular carcinoma development in viral hepatitis. (21883739)
2011
25
Epidermal growth factor induces cytokeratin 19 expression accompanied by increased growth abilities in human hepatocellular carcinoma. (20856226)
2011
26
DEC1 nuclear expression: a marker of differentiation grade in hepatocellular carcinoma. (21528084)
2011
27
Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. (19898900)
2010
28
Expression of I+-taxilin in hepatocellular carcinoma correlates with growth activity and malignant potential of the tumor. (21042709)
2010
29
Expression characteristics of nuclear factor kappa B in hepatocellular carcinoma tissues]. (19958645)
2009
30
Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. (19391065)
2009
31
Association analysis between the Cdc6 G1321A polymorphism and the risk for non-Hodgkin lymphoma and hepatocellular carcinoma. (19101572)
2009
32
Glycomic analysis of alpha-fetoprotein L3 in hepatoma cell lines and hepatocellular carcinoma patients. (18479159)
2008
33
Methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) gene polymorphisms as risk factors for hepatocellular carcinoma in a Korean population. (19035314)
2008
34
Transfer of suppressor of cytokine signaling 3 by an oncolytic adenovirus induces potential antitumor activities in hepatocellular carcinoma. (17935223)
2008
35
UDP-glucuronosyltransferase UGT1A7 genetic polymorphisms in hepatocellular carcinoma: a differential impact according to seropositivity of HBV or HCV markers? (18021430)
2007
36
Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. (17143948)
2006
37
Expression of epithelial cellular adhesion molecule (Ep-CAM) in chronic (necro-)inflammatory liver diseases and hepatocellular carcinoma. (16364680)
2006
38
Acyclic retinoid in the chemoprevention of hepatocellular carcinoma (review). (15010815)
2004
39
High levels of p53 protein expression do not correlate with p53 mutations in hepatocellular carcinoma. (15500550)
2004
40
CD44 and VEGF expression in extrahepatic metastasis of human hepatocellular carcinoma. (15239258)
2004
41
HEPN1, a novel gene that is frequently down-regulated in hepatocellular carcinoma, suppresses cell growth and induces apoptosis in HepG2 cells. (12971969)
2003
42
Factors related to acute upper gastrointestinal bleeding after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma]. (12478898)
2002
43
Relationship between the expression of PTEN protein and phosphorylation of MAPK in hepatocellular carcinomas and their surrounding liver tissues]. (12575334)
2002
44
Subacute cutaneous lupus erythematosus associated with hepatocellular carcinoma. (11309033)
2001
45
Up-regulation of peripheral benzodiazepine receptor system in hepatocellular carcinoma. (9771915)
1998
46
Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. (9605771)
1998
47
Detection of a unique gamma-glutamyl transpeptidase messenger RNA species closely related to the development of hepatocellular carcinoma in humans: a new candidate for early diagnosis of hepatocellular carcinoma. (8621139)
1996
48
Hepatocellular carcinoma associated with alcoholic liver disease: a clinicopathological study and genetic polymorphism of aldehyde dehydrogenase 2. (8986242)
1996
49
Thyroxine-binding globulin, hyperthyroxinemia and hepatocellular carcinoma. (1849117)
1991
50
Late recurrence of a hepatocellular carcinoma in a patient with incomplete Alagille syndrome. (2170223)
1990

Variations for Hepatocellular Carcinoma

About this section

UniProtKB/Swiss-Prot genetic disease variations for Hepatocellular Carcinoma:

68 (show all 21)
id Symbol AA change Variation ID SNP ID
1AXIN1p.Leu106ArgVAR_015589
2AXIN1p.Pro345LeuVAR_015590rs779951904
3AXIN1p.Gly425SerVAR_015591rs116350678
4AXIN1p.Gly650SerVAR_015592rs117208012
5CDKN3p.Trp31ArgVAR_013842
6CDKN3p.Phe78LeuVAR_013843
7CDKN3p.Cys79TyrVAR_013844
8CDKN3p.Asn91LysVAR_013845rs760687800
9CDKN3p.Asp94ValVAR_013846
10CDKN3p.Leu95PheVAR_013847
11CDKN3p.Ile108ValVAR_013848rs144479038
12CDKN3p.Asn187SerVAR_013849
13CDKN3p.Lys195IleVAR_013850
14METp.Thr1173IleVAR_032490rs121913675
15METp.Lys1244ArgVAR_032492rs121913677
16METp.Met1250IleVAR_032493rs121913676
17MTUS1p.Gln75LysVAR_035173rs61733703
18MTUS1p.Ala563SerVAR_035178
19MTUS1p.Asn873HisVAR_035180rs187103704
20MTUS1p.Gln1201ArgVAR_035184rs567116808
21PIK3CAp.Glu545AlaVAR_026176rs121913274

Clinvar genetic disease variations for Hepatocellular Carcinoma:

5 (show all 13)
id Gene Variation Type Significance SNP ID Assembly Location
1TP53NM_000546.5(TP53): c.747G> T (p.Arg249Ser)single nucleotide variantPathogenicrs28934571GRCh37Chr 17, 7577534: 7577534
2TP53NM_000546.5(TP53): c.469G> T (p.Val157Phe)single nucleotide variantPathogenicrs121912654GRCh37Chr 17, 7578461: 7578461
3PIK3CANM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg)single nucleotide variantPathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
4PIK3CANM_006218.3(PIK3CA): c.3203dupA (p.Asn1068Lysfs)duplicationPathogenicrs587776802GRCh37Chr 3, 178952148: 178952148
5PIK3CANM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala)single nucleotide variantPathogenicrs121913274GRCh37Chr 3, 178936092: 178936092
6IGF2RNM_000876.3(IGF2R): c.4346G> T (p.Gly1449Val)single nucleotide variantPathogenicrs121434587GRCh37Chr 6, 160490993: 160490993
7IGF2RNM_000876.3(IGF2R): c.4391G> A (p.Gly1464Glu)single nucleotide variantPathogenicrs121434588GRCh37Chr 6, 160491038: 160491038
8CTNNB1NM_001904.3(CTNNB1): c.134C> T (p.Ser45Phe)single nucleotide variantPathogenicrs121913409GRCh37Chr 3, 41266137: 41266137
9CTNNB1NM_001904.3(CTNNB1): c.133T> C (p.Ser45Pro)single nucleotide variantLikely pathogenic, Pathogenicrs121913407GRCh37Chr 3, 41266136: 41266136
10PDGFRLPDGRL, 2-BP DELdeletionPathogenic
11AXIN1NM_003502.3(AXIN1): c.1085_1116del32 (p.Val362Alafs)deletionPathogenicrs587776627GRCh38Chr 16, 309973: 310004
12CASP8NM_001228.4(CASP8): c.1279_1280delGT (p.Val427Phefs)deletionPathogenicrs587776665GRCh37Chr 2, 202149964: 202149965
13APCNM_000038.5(APC): c.1695delA (p.Val566Leufs)deletionPathogenicrs397514032GRCh37Chr 5, 112164621: 112164621

Cosmic variations for Hepatocellular Carcinoma:

8 (show top 50)    (show all 569)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM44321TP53liver,NS,carcinoma,hepatocellular carcinomac.712T>Cp.C238R0
2COSM516KRASbiliary tract,bile duct,carcinoma,NSc.34G>Tp.G12C0
3COSM43836TP53liver,NS,carcinoma,hepatocellular carcinomac.475G>Cp.A159P0
4COSM43919TP53liver,NS,carcinoma,hepatocellular carcinomac.856G>Tp.E286*0
5COSM5673CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.98C>Ap.S33Y0
6COSM520KRASbiliary tract,bile duct,carcinoma,NSc.35G>Tp.G12V0
7COSM43909TP53biliary tract,bile duct,carcinoma,NSc.817C>Ap.R273S0
8COSM28747IDH1biliary tract,bile duct,carcinoma,NSc.394C>Tp.R132C0
9COSM5674CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.104T>Gp.I35S0
10COSM44226TP53biliary tract,bile duct,carcinoma,NSc.380C>Tp.S127F0
11COSM583NRASliver,NS,carcinoma,hepatocellular carcinomac.182A>Tp.Q61L0
12COSM5682CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.97T>Cp.S33P0
13COSM521KRASbiliary tract,bile duct,carcinoma,NSc.35G>Ap.G12D0
14COSM133751AXIN1liver,NS,carcinoma,hepatocellular carcinomac.1184G>Cp.R395P0
15COSM44320TP53liver,NS,carcinoma,hepatocellular carcinomac.484A>Tp.I162F0
16COSM5663CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.133T>Cp.S45P0
17COSM143892AXIN1biliary tract,bile duct,carcinoma,NSc.2404G>Ap.G802S0
18COSM44241TP53liver,NS,carcinoma,hepatocellular carcinomac.592G>Tp.E198*0
19COSM517KRASbiliary tract,bile duct,carcinoma,NSc.34G>Ap.G12S0
20COSM522KRASbiliary tract,bile duct,carcinoma,NSc.35G>Cp.G12A0
21COSM44474TP53liver,NS,carcinoma,hepatocellular carcinomac.392A>Gp.N131S0
22COSM476BRAFbiliary tract,bile duct,carcinoma,NSc.1799T>Ap.V600E0
23COSM5664CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.121A>Gp.T41A0
24COSM5671CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.101G>Ap.G34E0
25COSM143921AXIN1liver,NS,carcinoma,hepatocellular carcinomac.1475G>Tp.R492L0
26COSM21483HNF1Aliver,NS,carcinoma,hepatocellular carcinomac.379A>Tp.N127Y0
27COSM4387483AXIN1liver,NS,carcinoma,hepatocellular carcinomac.1273G>Ap.G425S0
28COSM22932FBXW7biliary tract,bile duct,carcinoma,NSc.1393C>Tp.R465C0
29COSM10659TP53liver,NS,carcinoma,hepatocellular carcinomac.817C>Tp.R273C0
30COSM5661CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.94G>Tp.D32Y0
31COSM45992TP53liver,NS,carcinoma,hepatocellular carcinomac.736A>Tp.M246L0
32COSM5010401AXIN2liver,NS,carcinoma,hepatocellular carcinomac.260G>Ap.G87D0
33COSM5730CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.122C>Ap.T41N0
34COSM13636CDKN2Aliver,NS,carcinoma,hepatocellular carcinomac.272T>Ap.L91Q0
35COSM44322TP53liver,NS,carcinoma,hepatocellular carcinomac.728T>Ap.M243K0
36COSM12778NOTCH1liver,NS,carcinoma,hepatocellular carcinomac.7397C>Tp.T2466M0
37COSM143880AXIN1biliary tract,bile duct,carcinoma,NSc.683C>Tp.S228L0
38COSM46161TP53liver,NS,carcinoma,hepatocellular carcinomac.314G>Tp.G105V0
39COSM528KRASbiliary tract,bile duct,carcinoma,NSc.37G>Ap.G13S0
40COSM28750IDH1biliary tract,bile duct,carcinoma,NSc.395G>Tp.R132L0
41COSM13631CDKN2Aliver,NS,carcinoma,hepatocellular carcinomac.62C>Ap.A21D0
42COSM308020AGO1biliary tract,bile duct,carcinoma,NSc.1967G>Ap.R656H0
43COSM11542TP53liver,NS,carcinoma,hepatocellular carcinomac.703A>Gp.N235D0
44COSM584NRASbiliary tract,bile duct,carcinoma,NSc.182A>Gp.Q61R0
45COSM569NRASbiliary tract,bile duct,carcinoma,NSc.37G>Cp.G13R0
46COSM44093TP53biliary tract,bile duct,carcinoma,NSc.644G>Ap.S215N0
47COSM251401ARID1Aliver,NS,carcinoma,hepatocellular carcinomac.1210C>Tp.Q404*0
48COSM5686CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.100G>Ap.G34R0
49COSM44171TP53liver,NS,carcinoma,hepatocellular carcinomac.840A>Tp.R280S0
50COSM5691CTNNB1liver,NS,carcinoma,hepatocellular carcinomac.95A>Tp.D32V0

Copy number variations for Hepatocellular Carcinoma from CNVD:

6 (show top 50)    (show all 259)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1137721134600000DeletionHepatocellular carcinoma
2145131109179833109180141Copy numberFAM102BHepatocellular carcinoma
3145151109194253109194520Copy numberC1orf59Hepatocellular carcinoma
4164381124300000247249719GainHepatocellular carcinoma
5174011142600000165500000AmplificationHepatocellular carcinoma
6174041142600000207200000GainHepatocellular carcinoma
7193281149600000153300000GainADARLiver carcinoma
8193291149600000153300000GainC1orf43Liver carcinoma
9193301149600000153300000GainHAX1Liver carcinoma
10193311149600000163800000GainHepatocellular carcinoma
1120083115300000184000000GainTAGLN2Hepatocellular carcinoma
12206101153300000154800000GainCCT3Liver carcinoma
13208471154800000157300000GainCD1CLiver carcinoma
14208831155000000165500000AmplificationHepatocellular carcinoma
15212051157300000158800000GainNCSTNLiver carcinoma
16219831163800000165500000GainHepatocellular carcinoma
17221341165500000185800000AmplificationHepatocellular carcinoma
18236811172900000185800000AmplificationHepatocellular carcinoma
19251051184000000212100000LossPTPRCHepatocellular carcinoma
20256281192100000197500000GainCFHR2Liver carcinoma
21261511197500000205300000GainHepatocellular carcinoma
22262781198700000214500000AmplificationHepatocellular carcinoma
23262831198700000249250621GainHepatocellular carcinoma
24284991222700000225100000GainPYCR2Liver carcinoma
25298271236600000243700000AmplificationHepatocellular carcinoma
26298671237459374237459731Copy numberRYR2Hepatocellular carcinoma
273294714071084640711321Copy numberHepatocellular carcinoma
283359414650000060900000LossTGFBR3Hepatocellular carcinoma
293395315070000061300000DeletionHepatocellular carcinoma
30344708101232014101235406Copy numberPOLR2KLiver carcinoma
313582016779066567791040Copy numberIL12RB2Hepatocellular carcinoma
323583216790609367906510Copy numberHepatocellular carcinoma
33361081720000016200000Copy numberMTORHepatocellular carcinoma
3437059184900000117800000DeletionHepatocellular carcinoma
35381861016700000GainAKR1C3Hepatocellular carcinoma
363890210105800000135534747AmplificationHepatocellular carcinoma
3739998101230000017300000LossMRC1Hepatocellular carcinoma
3842451103440000038000000AmplificationC10orf9Hepatocellular carcinoma
3942452103440000038000000AmplificationCREMHepatocellular carcinoma
4042453103440000038000000AmplificationCUL2Hepatocellular carcinoma
4142454103440000038000000AmplificationCX40.1Hepatocellular carcinoma
4242455103440000038000000AmplificationFZD8Hepatocellular carcinoma
4342456103440000038000000AmplificationPARD3Hepatocellular carcinoma
4442799104020000042300000DeletionHepatocellular carcinoma
454832511121700000AmplificationHepatocellular carcinoma
46483531112800000Copy numberIGF2Hepatocellular carcinoma
474988111111568063111568201Copy numberSIK2Hepatocellular carcinoma
485002211112800000127400000LossSORL1Hepatocellular carcinoma
4957131116310000076700000LossESRRAHepatocellular carcinoma
5057452116340000077100000DeletionHepatocellular carcinoma

Expression for genes affiliated with Hepatocellular Carcinoma

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Hepatocellular Carcinoma patients vs. healthy controls: 33
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1EIF3Heukaryotic translation initiation factor 3, subunit HLiver+4.390.000
2C9complement component 9Liver-4.360.000
3UBDubiquitin DLiver+3.390.000
4PSMD6proteasome 26S subunit, non-ATPase 6Liver+3.230.000

Search GEO for disease gene expression data for Hepatocellular Carcinoma.

Pathways for genes affiliated with Hepatocellular Carcinoma

About this section

Pathways related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

(show all 22)
idSuper pathwaysScoreTop Affiliating Genes
110.8APC, AXIN1, CASP8, CTNNB1, MET, PIK3CA
2
Show member pathways
10.8APC, AXIN1, CTNNB1, GPC3, IGF2R, MET
3
Show member pathways
10.8CASP8, CTNNB1, IGF2R, MET, PIK3CA, TP53
4
Show member pathways
10.7APC, AXIN1, CTNNB1, PIK3CA, TP53
510.7APC, CASP8, CTNNB1, PIK3CA, TP53
6
Show member pathways
10.7APC, CTNNB1, MET, PIK3CA, TP53
710.7CTNNB1, GPC3, MET, PIK3CA, TP53
810.7APC, AXIN1, CTNNB1, PIK3CA
910.7APC, AXIN1, CTNNB1, TP53
1010.7APC, AXIN1, CTNNB1, TP53
11
Show member pathways
10.7APC, AXIN1, CTNNB1, TP53
12
Show member pathways
10.7APC, AXIN1, CTNNB1, TP53
13
Show member pathways
10.7APC, AXIN1, CTNNB1, TP53
1410.7APC, CTNNB1, PIK3CA, TP53
1510.7APC, AXIN1, CASP8, CTNNB1
1610.7AFP, APC, AXIN1, CTNNB1
1710.7AFP, APC, AXIN1, CTNNB1
1810.7AFP, APC, MET, TP53
1910.6AXIN1, CTNNB1, PIK3CA
2010.6APC, AXIN1, CTNNB1
2110.6CTNNB1, MET, PIK3CA
2210.6MET, PIK3CA, TP53

GO Terms for genes affiliated with Hepatocellular Carcinoma

About this section

Cellular components related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1Wnt signalosomeGO:199090910.8APC, CTNNB1
2catenin complexGO:001634210.8APC, CTNNB1
3beta-catenin destruction complexGO:003087710.7APC, AXIN1, CTNNB1
4lateral plasma membraneGO:001632810.6APC, AXIN1, CTNNB1

Biological processes related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1beta-catenin destruction complex disassemblyGO:190488611.0APC, AXIN1, CTNNB1
2beta-catenin destruction complex assemblyGO:190488511.0APC, AXIN1
3pancreas developmentGO:003101611.0AFP, APC, CTNNB1
4positive regulation of protein catabolic processGO:004573211.0APC, AXIN1, GPC3
5proteasome-mediated ubiquitin-dependent protein catabolic processGO:004316111.0APC, AXIN1, CTNNB1, TP53
6dorsal/ventral axis specificationGO:000995011.0AXIN1, CTNNB1
7liver developmentGO:000188910.7AFP, CTNNB1, IGF2R, PIK3CA
8negative regulation of cell proliferationGO:000828510.7APC, CDKN3, CTNNB1, GPC3, TP53
9canonical Wnt signaling pathwayGO:006007010.6APC, AXIN1, CTNNB1

Molecular functions related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1I-SMAD bindingGO:007041110.8AXIN1, CTNNB1
2protein phosphatase bindingGO:001990310.6CTNNB1, MET, TP53
3ubiquitin protein ligase bindingGO:003162510.4AXIN1, CASP8, MAGEC2, TP53

Sources for Hepatocellular Carcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet